Whether it´s oncolytic viruses or vectors for cancer therapy or modern vaccines, the demand for development, production or filling capacities is rising rapidly. To keep pace with this rise in customer demand, Vibalogics, which recently became part of the Recipharm Group, is investing around US$50m in the expansion of its Cuxhaven site by the end of the year, and even more in the US site near Boston.
A spotlight on tomorrow’s CRO
Sponsored PublicationsThe CRO industry is predicted to grow considerably over the next five years. Trials are becoming more complex, and technology is becoming increasingly interwoven with processes. The CRO of tomorrow must be tech smart, agile, and environmentally conscious to remain relevant. In this changing landscape, how does a CRO cut through the noise in 2022-30?
MaaT Pharma appointed new CSO
AppointmentsFrench MaaT Pharma has appointed Nathalie Corvaïa as Chief Scientific Officer and will strengthens its R&D Activities in Immuno-Oncology.
Araris Biotech closes $24m Series A financing round
Latest NewsSwiss ADC maker Araris Biotech AG has added a $24m financing round to its CHF15.2m (S17.8m) seed round in 2020 to expand its portfolio of proprietary antibody drug conjugates.
New Protein Fund I supports 17 alternative protein start-ups
Latest NewsWith money from its $50m New Protein Fund, Big Idea Ventures funds in 17 pre-seed plant-based, cell-based and microbial food, ingredient and technology companies.
Bringing virotherapy forward
BackgroundWhether it´s oncolytic viruses or vectors for cancer therapy or modern vaccines, the demand for development, production or filling capacities is rising rapidly. To keep pace with this rise in customer demand, Vibalogics, which recently became part of the Recipharm Group, is investing around US$50m in the expansion of its Cuxhaven site by the end of the year, and even more in the US site near Boston.
Sibylla Biotech raises €23m Series A
Latest NewsVerona-based Sibylla Biotech has closed a €23m Series A financing round to advance its Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI-FIT) platform.
Health: still a defensive position in portfolios?
OpinionHealthcare has long been considered one of the most reliable defensive sectors – an effective portfolio buffer when equity markets turn volatile. That’s because hospitals, drug makers, medical device firms and other companies across the healthcare sector benefit from steady consumer demand – still true?
AI expert XUND GmbH bags €6m seed financing
Latest NewsAustrian XUND GmbH wants to use the assets of a €6m seed financing to grow in Germany, Switzerland and Austria.
The BIOTECH Insight Newsletter presents news from biotechnology and german stock market
BackgroundIn the present newsletter special issues will be reinforced and personality of branches interviewed. Financing in sustainable production (#BRAIN_AG), synBio and AI (AIgnostics) are highlights in the Biotech Newsletter of Deutsche Börse AG.
ADC makeer Pheon Therapeutics raises $68m
Latest NewsAntibody-Drug Conjugate (ADC) specialist Pheon Therapeutics Ltd. has closed a $68m Series A financing co-led by Brandon Capital, Forbion and Atlas Venture.